Nicardipine improves the antidepressant action of ECT but does not improve cognition

Steven L. Dubovsky, Randall Buzan, Marshall Thomas, Cordt Kassner, C. Munro Cullum

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Introduction: Cognitive impairment, the most important adverse effect of electroconvulsive therapy (ECT), may involve elevated intracellular calcium ion signaling. Animal research suggests that calcium channel-blocking agents, which attenuate excessive intracellular calcium activity, may reduce cognitive dysfunction caused by ECT. Method: The lipid-soluble calcium channel-blocking drug nicardipine or matching placebo were randomly assigned to 26 patients with major depressive disorder receiving ECT. A rater blind to the experimental condition administered the Hamilton Depression Rating Scale, the Montgomery-Asberg Depression Rating Scale, the Beck Depression Inventory, the Mini-Mental State Examination and a comprehensive battery of neuropsychological tests prior to ECT, at the completion of ECT, and 6 months after ECT completion. Results: Compared with patients receiving placebo, patients taking nicardipine had significantly lower scores on the Hamilton and Montgomery-Asberg but not the Beck Depression rating scale scores at the completion of ECT. There were no differences between placebo and nicardipine groups in depression scores 6 months after ECT. Cognitive function declined over the course of ECT and improved over the next 6 months in both groups, but changes were statistically significant for only two subtests on the neuropsychological battery. Changes in Mini-Mental State Examination scores were small and were not significant at any point. There were no significant differences between nicardipine and placebo treated groups in any assessment of cognition. Discussion: Standard approaches to ECT in younger patients without preexisting neurological impairment do not produce cognitive side effects of sufficient severity for calcium channel-blocking agents to reduce these side effects demonstrably. Studies of treatments for cognitive impairment should be conducted in patients with risk factors for more severe cognitive impairment such as geriatric patients or patients with a history of interictal delirium during previous treatment with ECT. A possible effect of nicardipine in enhancing the antidepressant action of ECT requires further investigation in a study designed to test this action.

Original languageEnglish (US)
Pages (from-to)3-10
Number of pages8
JournalJournal of ECT
Volume17
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Nicardipine
Electroconvulsive Therapy
Cognition
Antidepressive Agents
Depression
Placebos
Calcium Channels
Calcium Signaling
Delirium
Neuropsychological Tests
Major Depressive Disorder
Calcium Channel Blockers
Geriatrics

Keywords

  • Calcium channel-blocking agents
  • Cognitive impairment
  • Electroconvulsive therapy
  • Nicardipine

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Nicardipine improves the antidepressant action of ECT but does not improve cognition. / Dubovsky, Steven L.; Buzan, Randall; Thomas, Marshall; Kassner, Cordt; Cullum, C. Munro.

In: Journal of ECT, Vol. 17, No. 1, 2001, p. 3-10.

Research output: Contribution to journalArticle

Dubovsky, Steven L. ; Buzan, Randall ; Thomas, Marshall ; Kassner, Cordt ; Cullum, C. Munro. / Nicardipine improves the antidepressant action of ECT but does not improve cognition. In: Journal of ECT. 2001 ; Vol. 17, No. 1. pp. 3-10.
@article{30242009c0574f40b6865d53a89947ae,
title = "Nicardipine improves the antidepressant action of ECT but does not improve cognition",
abstract = "Introduction: Cognitive impairment, the most important adverse effect of electroconvulsive therapy (ECT), may involve elevated intracellular calcium ion signaling. Animal research suggests that calcium channel-blocking agents, which attenuate excessive intracellular calcium activity, may reduce cognitive dysfunction caused by ECT. Method: The lipid-soluble calcium channel-blocking drug nicardipine or matching placebo were randomly assigned to 26 patients with major depressive disorder receiving ECT. A rater blind to the experimental condition administered the Hamilton Depression Rating Scale, the Montgomery-Asberg Depression Rating Scale, the Beck Depression Inventory, the Mini-Mental State Examination and a comprehensive battery of neuropsychological tests prior to ECT, at the completion of ECT, and 6 months after ECT completion. Results: Compared with patients receiving placebo, patients taking nicardipine had significantly lower scores on the Hamilton and Montgomery-Asberg but not the Beck Depression rating scale scores at the completion of ECT. There were no differences between placebo and nicardipine groups in depression scores 6 months after ECT. Cognitive function declined over the course of ECT and improved over the next 6 months in both groups, but changes were statistically significant for only two subtests on the neuropsychological battery. Changes in Mini-Mental State Examination scores were small and were not significant at any point. There were no significant differences between nicardipine and placebo treated groups in any assessment of cognition. Discussion: Standard approaches to ECT in younger patients without preexisting neurological impairment do not produce cognitive side effects of sufficient severity for calcium channel-blocking agents to reduce these side effects demonstrably. Studies of treatments for cognitive impairment should be conducted in patients with risk factors for more severe cognitive impairment such as geriatric patients or patients with a history of interictal delirium during previous treatment with ECT. A possible effect of nicardipine in enhancing the antidepressant action of ECT requires further investigation in a study designed to test this action.",
keywords = "Calcium channel-blocking agents, Cognitive impairment, Electroconvulsive therapy, Nicardipine",
author = "Dubovsky, {Steven L.} and Randall Buzan and Marshall Thomas and Cordt Kassner and Cullum, {C. Munro}",
year = "2001",
doi = "10.1097/00124509-200103000-00002",
language = "English (US)",
volume = "17",
pages = "3--10",
journal = "Journal of ECT",
issn = "1095-0680",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Nicardipine improves the antidepressant action of ECT but does not improve cognition

AU - Dubovsky, Steven L.

AU - Buzan, Randall

AU - Thomas, Marshall

AU - Kassner, Cordt

AU - Cullum, C. Munro

PY - 2001

Y1 - 2001

N2 - Introduction: Cognitive impairment, the most important adverse effect of electroconvulsive therapy (ECT), may involve elevated intracellular calcium ion signaling. Animal research suggests that calcium channel-blocking agents, which attenuate excessive intracellular calcium activity, may reduce cognitive dysfunction caused by ECT. Method: The lipid-soluble calcium channel-blocking drug nicardipine or matching placebo were randomly assigned to 26 patients with major depressive disorder receiving ECT. A rater blind to the experimental condition administered the Hamilton Depression Rating Scale, the Montgomery-Asberg Depression Rating Scale, the Beck Depression Inventory, the Mini-Mental State Examination and a comprehensive battery of neuropsychological tests prior to ECT, at the completion of ECT, and 6 months after ECT completion. Results: Compared with patients receiving placebo, patients taking nicardipine had significantly lower scores on the Hamilton and Montgomery-Asberg but not the Beck Depression rating scale scores at the completion of ECT. There were no differences between placebo and nicardipine groups in depression scores 6 months after ECT. Cognitive function declined over the course of ECT and improved over the next 6 months in both groups, but changes were statistically significant for only two subtests on the neuropsychological battery. Changes in Mini-Mental State Examination scores were small and were not significant at any point. There were no significant differences between nicardipine and placebo treated groups in any assessment of cognition. Discussion: Standard approaches to ECT in younger patients without preexisting neurological impairment do not produce cognitive side effects of sufficient severity for calcium channel-blocking agents to reduce these side effects demonstrably. Studies of treatments for cognitive impairment should be conducted in patients with risk factors for more severe cognitive impairment such as geriatric patients or patients with a history of interictal delirium during previous treatment with ECT. A possible effect of nicardipine in enhancing the antidepressant action of ECT requires further investigation in a study designed to test this action.

AB - Introduction: Cognitive impairment, the most important adverse effect of electroconvulsive therapy (ECT), may involve elevated intracellular calcium ion signaling. Animal research suggests that calcium channel-blocking agents, which attenuate excessive intracellular calcium activity, may reduce cognitive dysfunction caused by ECT. Method: The lipid-soluble calcium channel-blocking drug nicardipine or matching placebo were randomly assigned to 26 patients with major depressive disorder receiving ECT. A rater blind to the experimental condition administered the Hamilton Depression Rating Scale, the Montgomery-Asberg Depression Rating Scale, the Beck Depression Inventory, the Mini-Mental State Examination and a comprehensive battery of neuropsychological tests prior to ECT, at the completion of ECT, and 6 months after ECT completion. Results: Compared with patients receiving placebo, patients taking nicardipine had significantly lower scores on the Hamilton and Montgomery-Asberg but not the Beck Depression rating scale scores at the completion of ECT. There were no differences between placebo and nicardipine groups in depression scores 6 months after ECT. Cognitive function declined over the course of ECT and improved over the next 6 months in both groups, but changes were statistically significant for only two subtests on the neuropsychological battery. Changes in Mini-Mental State Examination scores were small and were not significant at any point. There were no significant differences between nicardipine and placebo treated groups in any assessment of cognition. Discussion: Standard approaches to ECT in younger patients without preexisting neurological impairment do not produce cognitive side effects of sufficient severity for calcium channel-blocking agents to reduce these side effects demonstrably. Studies of treatments for cognitive impairment should be conducted in patients with risk factors for more severe cognitive impairment such as geriatric patients or patients with a history of interictal delirium during previous treatment with ECT. A possible effect of nicardipine in enhancing the antidepressant action of ECT requires further investigation in a study designed to test this action.

KW - Calcium channel-blocking agents

KW - Cognitive impairment

KW - Electroconvulsive therapy

KW - Nicardipine

UR - http://www.scopus.com/inward/record.url?scp=0035079933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035079933&partnerID=8YFLogxK

U2 - 10.1097/00124509-200103000-00002

DO - 10.1097/00124509-200103000-00002

M3 - Article

VL - 17

SP - 3

EP - 10

JO - Journal of ECT

JF - Journal of ECT

SN - 1095-0680

IS - 1

ER -